Dublin, Aug. 31, 2020 (GLOBE NEWSWIRE) -- The "In Situ Hybridization (ISH) Market by Product (Consumables (Kits, Probes) Software), Technology (FISH (DNA, RNA), CISH), Application (Cancer, Infectious Disease), and End User (Diagnostic Labs, Research Institutes, CROs), Region - Global Forecast to 2025" report has been added to ResearchAndMarkets.com's offering.
The global in situ hybridization (ISH) market size is projected to reach USD 1.3 billion by 2025 from USD 0.9 billion in 2020, at a CAGR of 7.4% during the forecast period.
The increasing incidence of cancer and awareness of companion diagnostics test are the major factors driving the growth of this market. However, the lack of skilled professionals poses a challenge to the ISH market.
By consumables type, the kits & reagents accounted for the fastest-growing segment of the ISH market.
The kits & reagents segment accounted for the largest share of this market in 2019. The rise in government and private funding in life sciences and cancer research, the increasing number of reagent rental agreements, and the application of innovative technologies and methodologies in the fields of tissue and in vitro diagnostics are expected to drive the growth of the ISH consumables market during the forecast period.
By technology type, the FISH segment accounted for the largest share of the ISH market.
Based on technology, the ISH market is segmented broadly into fluorescence in situ hybridization (FISH) and chromogenic in situ hybridization (CISH). This segment accounted for the largest share of the global ISH market in 2019. The large share of this segment is attributed to the increasing demand for FISH kits and assays in CDx for cancer diagnostics, chromosomal abnormalities, and infectious diseases.
Asia Pacific: The fastest-growing region in the ISH market.
The Asia Pacific market is projected to grow at the highest CAGR during the forecast period, The economic growth in the countries of this region, its large population base, the rising prevalence of chronic diseases, improvements in the standard of living, growing demand for quality medical care, increasing healthcare spending, government initiatives, and awareness regarding the use of tissue diagnostic tests (including ISH) are the major factors driving market growth in the APAC
North America: the largest share of the ISH market.
North America accounted for the largest share of the ISH market. The large share of this segment can primarily be attributed to the presence of major players operating in the ISH market in the US, rising incidence of cancer and infectious diseases, and the increasing adoption of companion diagnostic assay kits.
Key Topics Covered:
1 Introduction
2 Research Methodology
3 Executive Summary
4 Premium Insights
4.1 In Situ Hybridization Market Overview
4.2 Asia-Pacific: In Situ Hybridization Market Share, by End-user and Country (2019)
4.3 In Situ Hybridization Market, by Product
4.4 In Situ Hybridization Market Share, by Technology, 2020 Vs. 2025
4.5 In Situ Hybridization Consumables Market, by Type, 2020 Vs. 2025 (Usd Million)
5 Market Overview
5.1 Introduction
5.2 Market Dynamics
5.2.1 Market Drivers
5.2.1.1 Increasing Incidence of Genetic Disorders and Cancer
5.2.1.2 Awareness About Companion Diagnostics
5.2.2 Opportunities
5.2.2.1 Untapped Markets in Developing Countries
5.2.3 Challenges
5.2.3.1 Lack of Skilled Professionals
5.3 Value Chain Analysis
5.4 Impact of the Covid-19 Outbreak on the Growth of the In Situ Hybridization Market
6 In Situ Hybridization Market, by Product
6.1 Introduction
6.2 Consumables
6.2.1 Kits & Reagents
6.2.1.1 Increasing Focus on Companion Diagnostics Has Driven Market Demand for Kits & Reagents
6.2.2 Probes
6.2.2.1 Preference for Direct Localization of Dna/Rna Sequences Using Probes is Likely to Drive the Market
6.2.3 Accessories
6.3 Instruments
6.3.1 Need for Automated Systems Supports Market Growth
6.4 Software
6.4.1 Demand for Software is Driven by the Need for High-Speed Sample Data Analysis
7 In Situ Hybridization Market, by Technology
7.1 Introduction
7.2 Fluorescence In Situ Hybridization
7.2.1 DNA Fluorescence In Situ Hybridization
7.2.1.1 Need to Ensure the Stability of Genetic Material Likely to Drive the Market
7.2.2 Rna Fluorescence In Situ Hybridization
7.2.2.1 Rise in Biomedical Research Activity Has Supported Market Growth
7.2.3 PNA Fluorescence In Situ Hybridization
7.2.3.1 Increased Application in Infectious Disease Resulted in Market Growth
7.3 Chromogenic In Situ Hybridization
7.3.1 Cost-Effectiveness Over Fluorescence In Situ Hybridization Fish Supports Market Growth
8 In Situ Hybridization Market, by Application
8.1 Introduction
8.2 Cancer Diagnostics
8.2.1 Increasing Importance in Companion Diagnostics to Drive Market Growth
8.3 Cytology
8.3.1 Fish is Preferred in the Detection of Chromosomal Abnormalities
8.4 Infectious Disease Diagnostics
8.4.1 Need for High Sensitivity and Specificity in Infectious Diagnosis is Likely to Support Market Growth
8.5 Neuroscience
8.5.1 Rising Burden of Neurological Disorders Has Boosted Overall R&D Activity
8.6 Immunology
8.6.1 Rising Incidence of Autoimmune Diseases Supports Market Growth
9 In Situ Hybridization Market, by End-user
9.1 Introduction
9.2 Hospital & Diagnostic Laboratories
9.2.1 Demand for Molecular Tests to Drive Market Growth
9.3 Academic & Research Institutes
9.3.1 Increasing Research on Chromosomal Abnormalities Will Support Market Growth
9.4 Pharmaceutical & Biotechnology Companies
9.4.1 Need to Develop Precision Treatments Drives Demand for In Situ Hybridization
9.5 Contract Research Organizations
9.5.1 Increasing Outsourcing of Research Activities to Support Market Growth
10 In Situ Hybridization Market, by Region
10.1 Introduction
10.2 North America
10.3 Europe
10.4 Asia-Pacific
10.5 Rest of the World
11 Competitive Landscape
11.1 Introduction
11.2 Market Ranking Analysis
11.3 Market Evaluation Framework
11.4 Competitive Scenario
11.4.1 Key Product Launches
11.4.2 Key Collaborations & Agreements
11.4.3 Key Expansions
12 Company Evaluation Matrix and Company Profiles
12.1 Overview
12.2 In Situ Hybridization Market: Company Evaluation Matrix
12.2.1 Stars
12.2.2 Emerging Leaders
12.2.3 Pervasive Companies
12.2.4 Emerging Companies
12.3 Company Profiles
12.3.1 Abbott Laboratories
12.3.2 F. Hoffmann-La Roche
12.3.3 Agilent Technologies
12.3.4 Thermo Fisher Scientific
12.3.5 Bio-Techne Corporation
12.3.6 Qiagen N.V.
12.3.7 Danaher Corporation
12.3.8 Perkinelmer
12.3.9 Enzo Biochem
12.3.10 Bio-Rad Laboratories
12.3.11 Merck Kgaa
12.3.12 Abnova Corporation
12.3.13 Biogenex Laboratories
12.3.14 Biocare Medical
12.3.15 Opgen
12.3.16 Bio Sb
12.3.17 Genemed Biotechnologies
12.3.18 Abcam
12.3.19 Creative Bioarray
12.3.20 Biocat GmbH
12.3.21 Zytovision
13 Appendix
For more information about this report visit https://www.researchandmarkets.com/r/or7mgu
Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.